Home > Insider Trading > Filing (0000899243-19-005313)

Filing Details

Accession Number:: 0000899243-19-005313
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2019-02-28 19:21:37
Reporting Period:: 2019-02-26

Accepted Time:: 2019-02-28 19:21:37
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1367644	Emergent Biosolutions Inc.	EBS	Pharmaceutical Preparations (2834)	141902018

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1380185	Fuad El-Hibri	400 Professional Drive, Suite 400 Gaithersburg MD 20879	Chairman	Yes	Yes	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Disposition	2019-02-26	10,369	$59.65	1,478,306	No	4	S	Direct
Common Stock	Acquisiton	2019-02-26	6,430	$0.00	1,484,736	No	4	M	Direct
Common Stock	Disposition	2019-02-26	1,566	$61.01	1,483,170	No	4	F	Direct
Common Stock	Disposition	2019-02-27	10,369	$58.24	1,472,801	No	4	S	Direct
Common Stock	Acquisiton	2019-02-27	9,794	$0.00	1,482,595	No	4	M	Direct
Common Stock	Disposition	2019-02-27	2,486	$57.98	1,480,109	No	4	F	Direct
Common Stock	Disposition	2019-02-28	6,987	$58.47	1,473,122	No	4	S	Direct
Common Stock	Acquisiton	2019-02-28	9,722	$0.00	1,482,844	No	4	M	Direct
Common Stock	Disposition	2019-02-28	3,826	$58.71	1,479,018	No	4	F	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	S	Direct
No	4	M	Direct
No	4	F	Direct
No	4	S	Direct
No	4	M	Direct
No	4	F	Direct
No	4	S	Direct
No	4	M	Direct
No	4	F	Direct

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Restricted Stock Units	Disposition	2019-02-26	6,430	$0.00	6,430	$0.00
Common Stock	Restricted Stock Units	Acquisiton	2019-02-26	18,029	$0.00	18,029	$0.00
Common Stock	Stock Options (Right to Buy)	Acquisiton	2019-02-26	36,053	$0.00	36,053	$61.01
Common Stock	Restricted Stock Units	Disposition	2019-02-27	9,794	$0.00	9,794	$0.00
Common Stock	Restricted Stock Units	Disposition	2019-02-28	9,722	$0.00	9,722	$0.00

Remaning Holdings	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
42,168		No	4	M	Direct
60,197		No	4	A	Direct
36,053	2026-02-25	No	4	A	Direct
50,403		No	4	M	Direct
40,681		No	4	M	Direct

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	4,344,250	Indirect	By Intervac, L.L.C.
Common Stock	1,524,155	Indirect	By Biovac, L.L.C.

Footnotes

All sales listed on this Form 4 were made by Mr. El-Hibri pursuant to a trading plan adopted on June 6, 2018 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934 (the "Exchange Act").
The price reported reflects a weighted average price. These shares were sold in multiple transactions at prices ranging from $58.40 to $61.21.
Restricted stock units convert into common stock on a one-for-one basis.
The price reported reflects a weighted average price. These shares were sold in multiple transactions at prices ranging from $56.96 to $59.08.
The price reported reflects a weighted average price. These shares were sold in multiple transactions at prices ranging from $57.54 to $59.25.
Mr. El-Hibri's wife, individually, and Mr. and Mrs. El-Hibri, as tenants by the entirety, collectively hold an aggregate 40.65% equity interest in Intervac, L.L.C., which in turn is the direct owner of 4,344,250 shares of the Issuer's common stock. Mr. El-Hibri disclaims beneficial ownership of the shares of the Issuer's common stock directly owned by Intervac, L.L.C. for purposes of Section 16 of the Exchange Act or otherwise, except to the extent of his pecuniary interest therein.
Mr. El-Hibri, individually, and Mr. and Mrs. El-Hibri, as tenants by the entirety, collectively hold an aggregate 89.2% equity interest in Biovac, L.L.C, which in turn is the direct owner of 1,524,155 shares of the Issuer's common stock. Mr. El-Hibri disclaims beneficial ownership of the shares of the Issuer's common stock directly owned by Biovac, L.L.C. for purposes of Section 16 of the Exchange Act or otherwise, except to the extent of his pecuniary interest therein.
On February 27, 2018, Mr. El-Hibri was granted 19,288 restricted stock units vesting in three approximately equal annual installments beginning on the day prior to the first anniversary of the grant date.
On February 26, 2019, Mr. El-Hibri was granted 18,029 restricted stock units vesting in three approximately equal annual installments beginning on the day prior to the first anniversary of the grant date.
On February 26, 2019, Mr. El-Hibri was granted 36,053 stock options vesting in three approximately equal annual installments beginning on the day prior to the first anniversary of the grant date.
On February 28, 2017, Mr. El-Hibri was granted 29,382 restricted stock units vesting in three approximately equal annual installments beginning on the day prior to the first anniversary of the grant date.
On March 1, 2016, Mr. El-Hibri was granted 29,167 restricted stock units (after giving effect to the adjustment in connection with the Issuer's spin-off of Aptevo Therapeutics Inc.) vesting in three approximately equal annual installments beginning on the day prior to the first anniversary of the grant date.